TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07578012: A Randomized Double-blind Placebo-controlled Study to Demonstrate the Efficacy of PMBL® Sublingual Tablets in Reducing the Incidence of Respiratory Tract Infections in Children Aged 3-12 Years (PIRTIK).

Sponsor: Lallemand Pharma AG · Phase: PHASE4 · Area: INFECTIOUS_VACCINE · Target Enrollment: 224 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,021,920

Rescue Site Savings

+$2,657,760

Unlock Full NCT07578012 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07578012 Rescue Dossier →